Skip to main content
Fig. 2 | Trials

Fig. 2

From: Kunxian capsules in the treatment of patients with ankylosing spondylitis: a randomized placebo-controlled clinical trial

Fig. 2

The changes of ASAS 20, BASDAI 50, ASDAS-CRP, and CRP at weeks 0, 2, 6, and 12 in the patients with ankylosing spondylitis treated with Kunxian. a ASAS 20 in Kunxian group was significantly higher than that in placebo group at week 12 (p < 0.05). b BASDAI 50 in Kunxian group was significantly higher than that in placebo group at week 6 (p < 0.001). c ASDAS-CRP in Kunxian group was significantly higher than that in placebo group, especially at week 6 (p < 0.001). d The change of serum CRP in Kunxian and placebo groups. Serum CRP in Kunxian group was significantly lower than that in placebo group at weeks 2, 6, and 12 (p < 0.05)

Back to article page

Trials

ISSN: 1745-6215